A recent meal or snack does not affect the pharmacological profile of trofinetide, an experimental oral treatment for…
Marisa Wexler, MS
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Wexler, MS
Unravel Biosciences, which is working toward a first clinical trial to test its investigational therapy RVL001 in people with…
Treatment with a modified version of the MeCP2 protein, one designed to better get into cells, markedly extended lifespans in…
The European Commission is expected to propose a new governing framework for health data next month, called the European Health…
The protein MeCP2 normally forms a complex with several other proteins in the brain that helps to regulate the development…
A molecular sensor of infections called the NLRP3 inflammasome is overactive in immune cells of people with Rett syndrome,…
The Rett Syndrome Research Trust (RSRT) has invested $3.1 million in a slew of research projects as part of its…
A cellular signaling pathway called the JNK pathway is overactive in cell and animal models of Rett syndrome, and…
The MECP2 gene — mutations in which cause most cases of Rett syndrome — may be important for encoding early childhood…
A newly found mutation in the MECP2 gene that causes Rett syndrome was described in a recent report. The…